Search results
Showing 1 to 6 of 6 results for brolucizumab
Evidence-based recommendations on brolucizumab (Beovu) for diabetic macular oedema in adults.
Brolucizumab for treating wet age-related macular degeneration (TA672)
Evidence-based recommendations on brolucizumab (Beovu) for treating wet age-related macular degeneration in adults.
Bevacizumab gamma for treating wet age-related macular degeneration [ID6320]
In development [GID-TA11193] Expected publication date: 04 December 2024
This guideline covers managing and monitoring diabetic retinopathy in people under the care of hospital eye services. This includes non-proliferative and proliferative diabetic retinopathy, and diabetic macular oedema.
Supporting the health and care system in improving productivity
Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.
Supporting the health and care system in improving productivity
Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.